UK-based pharmaceutical company Phagenesis closed its €7m ($9.3m) of series B funding yesterday with Inventages, a life sciences firm backed by Switzerland-based food and nutrition corporation Nestlé, leading the round. 

Founded in 2007 after it span off from research performed at the University of Manchester, Phagenesis raised £2m ($3.1m) in a September 2010 series A round of financing from unnamed investors. Phagenesis is developing a device that will help dysphagia sufferers to swallow, using controlled electrical pulses.

Gunnar Weikert,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?